Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2007 Jan 29;96(2):189-95.
doi: 10.1038/sj.bjc.6603515. Epub 2007 Jan 9.

DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents

J P B O'Connor  1 , A Jackson, G J M Parker, G C Jayson
Affiliations
Review

DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents

J P B O'Connor et al. Br J Cancer. .

Abstract

Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is now frequently used in early clinical trial assessment of antiangiogenic and vascular disrupting compounds. Evidence of drug efficacy and dose-dependent response has been demonstrated with some angiogenesis inhibitors. This review highlights the critical issues that influence T(1)-weighted DCE-MRI data acquisition and analysis, identifies important areas for future development and reviews the clinical trial findings to date.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Compartmental modelling of the tumour microvasculature: blood flows through the tumour enabling contrast media molecules (represented as black dots) to distribute in two potential compartments – the blood plasma volume vp and the volume of the extravascular extracellular space ve. Clinically available MRI contrast agents do not leak into the intracellular space vi. Contrast agent leakage is governed by the concentration difference between the plasma and the extracellular extravascular space and by the permeability and surface area of the capillary endothelia, expressed as PS.
See this image and copyright information in PMC

References

    1. Baluk P, Hashizume H, McDonald DM (2005) Cellular abnormalities of blood vessels as targets in cancer. Curr Opin Genet Dev 15: 102–111 - PubMed
    1. Buonaccorsi GA, Roberts C, Cheung S, Watson Y, O'Connor JP, Davies K, Jackson A, Jayson GC, Parker GJ (2006) Comparison of the performance of tracer kinetic model-driven registration for dynamic contrast enhanced MRI using different models of contrast enhancement. Acad Radiol 13: 1112–1123 - PubMed
    1. Conrad C, Friedman H, Reardon D, Provenzale J, Jackson E, Serajuddin H, Laurent D, Chen B, Yung WKA (2004) A phase I/II trial of single-agent PTK 787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in patients with recurrent glioblastoma multiforme (GBM). J Clin Oncol (Meetings Abstracts) 22(14S): 1512
    1. Dowlati A, Robertson K, Cooney M, Petros WP, Stratford M, Jesberger J, Rafie N, Overmoyer B, Makkar V, Stambler B, Taylor A, Waas J, Lewin JS, McCrae KR, Remick SC (2002) A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res 62: 3408–3416 - PubMed
    1. Drevs J, Medinger M, Mross K, Zirrgiebel U, Strecker R, Unger C, Puchalski TA, Fernandes N, Roberston J, Siegert P (2005) Phase I clinical evaluation of AZD2171, a highly potent VEGF receptor tyrosine kinase inhibitor, in patients with advanced tumors. J Clin Oncol (Meetings Abstracts) 23(16S): 3002

Publication types

MeSH terms